MADRIGAL PHARMACEUTICALS, INC.

MDGL

MADRIGAL PHARMACEUTICALS, INC.

MDGL

Insider Sentiment (TTM):

Last Purchase:2025-08-20Last Sale:2026-06-01Shares Purchased (TTM):0Shares Sold (TTM):104,585

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:23,046,789Shares Outstanding:29,032,422Institutional Ownership Pct.:79.38%

Earnings Market Reaction:

Filing Date:2026-07-30Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	293	227	199	296	186	184	100	233	495	623	100	62
Restricted Cash	-	-	-	5	5	5	-	5	5	-	-	-
Restricted Cash Current	0	5	5	-	-	-	5	-	-	-	0	-
Available For Sale Securities Debt Securities Curr…	546	586	785	814	611	659	826	766	563	437	534	170
Accounts Receivable Net Current	192	187	134	113	79	61	54	30	7	-	0	-
Inventory Net	99	112	75	69	63	55	34	9	7	1	0	-
Prepaid Expense And Other Assets Current	69	65	48	49	59	23	14	21	15	14	3	3
Assets Current	1,199	1,182	1,246	1,347	1,003	988	1,033	1,064	1,092	1,074	637	235
Property Plant And Equipment Net	12	8	1	3	2	2	2	2	2	2	2	1
Finite Lived Intangible Assets Net	7	7	7	7	5	5	5	5	5	5	0	-
Operating Lease Right Of Use Asset	6	6	5	5	6	2	2	3	1	2	2	2
Other Assets Noncurrent	21	23	-	-	-	-	-	-	-	-	-	-
Assets	1,245	1,227	1,260	1,362	1,015	997	1,042	1,073	1,100	1,082	641	238
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current	35	61	49	45	38	42	44	46	9	22	28	17
Accrued Liabilities Current	339	276	260	345	157	124	125	131	116	92	90	83
Operating Lease Liability Current	1	2	1	1	1	1	1	1	1	1	1	1
Liabilities Current	374	338	310	391	197	167	169	178	125	114	119	100
Liabilities Noncurrent
Long Term Debt Noncurrent	341	340	340	340	118	118	118	117	117	116	115	115
Operating Lease Liability Noncurrent	6	5	7	6	5	1	1	1	1	1	1	1
Liabilities Noncurrent	347	346	347	345	123	119	119	118	118	117	117	116
Liabilities	721	684	657	737	319	286	288	296	243	232	235	216
Stockholders Equity
Preferred Stock Value	0	0	0	0	0	0	0	0	0	0	0	-
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital Common Stock	2,766	2,727	2,692	2,657	2,613	2,586	2,556	2,519	2,493	2,335	1,741	1,246
Accumulated Other Comprehensive Income Loss Net Of…	1	1	1	1	1	0	0	1	-0	-0	0	-0
Retained Earnings Accumulated Deficit	-2,243	-2,185	-2,090	-2,032	-1,918	-1,875	-1,802	-1,743	-1,636	-1,484	-1,336	-1,224
Stockholders Equity	524	543	603	626	696	711	754	777	857	851	405	22
Liabilities And Stockholders Equity	1,245	1,227	1,260	1,362	1,015	997	1,042	1,073	1,100	1,082	641	238
Preferred Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Authorized	5	5	5	5	5	5	5	5	5	5	5	5
Preferred Stock Shares Issued	2	2	2	2	2	2	2	2	2	2	2	2
Preferred Stock Shares Outstanding	2	2	2	2	2	2	2	2	2	2	2	2
Common Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Shares Authorized	200	200	200	200	200	200	200	200	200	200	200	200
Common Stock Shares Issued	23	23	23	23	22	22	22	22	20	20	20	18
Shares Outstanding	23	23	23	23	22	22	22	22	20	20	20	18

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-7.87%	-5.02%	0.89%	-	-	-	-	-	-	-	-	-
2025	-18.35%	-12.81%	1.96%	29.19%	25.17%	24.37%	34.26%	34.70%	8.05%	1.82%	18.94%	16.75%
2024	8.35%	28.54%	30.52%	5.58%	-9.25%	-10.00%	33.97%	18.93%	13.23%	-4.01%	-15.24%	-18.24%
2023	-	-	-	9.51%	-13.62%	-28.78%	44.62%	57.01%	53.34%	-2.37%	-16.60%	-13.44%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	3.20	3.50	4.01	3.44	5.11	5.91	6.10	5.98	8.72	9.39	5.38	2.36
Quick Ratio	2.76	2.97	3.62	3.14	4.48	5.44	5.82	5.81	8.55	9.26	5.35	2.33
Working Capital	824.98M	844.05M	935.48M	955.27M	806.85M	820.74M	863.65M	885.82M	966.57M	959.61M	518.73M	135.80M
Leverage & Debt
Debt to Equity	1.38	1.26	1.09	1.18	0.46	0.40	0.38	0.38	0.28	0.27	0.58	9.70
Interest Coverage TTM	-10.24	-11.68	-13.45	-14.40	-17.63	-23.66	-26.90	-36.19	-35.43	-31.95	-29.93	-33.45
Debt Ratio	0.58	0.56	0.52	0.54	0.31	0.29	0.28	0.28	0.22	0.21	0.37	0.91
Efficiency & Turnover
Asset Turnover TTM	1.14	1.02	0.83	0.61	0.49	0.31	0.21	0.12	0.02	0.00	0.00	0.00
Days Sales Outstanding TTM	38.60	40.09	35.86	35.42	30.49	70.64	109.06	144.75	172.03	-	-	-
Receivables Turnover TTM	9.46	9.10	10.18	10.30	11.97	5.17	3.35	2.52	2.12	-	-	-
Per Share Metrics
Diluted EPS TTM	-11.15	-10.66	-12.85	-12.86	-9.98	-13.94	-21.90	-23.85	-23.85	-22.21	-19.99	-18.80
Free Cash Flow Per Share TTM	-7.10	-9.41	-8.50	-7.19	-10.92	-14.11	-21.48	-19.93	-21.06	-19.55	-17.43	-16.41
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Operating Profit Margin TTM	-25.13%	-27.68%	-31.31%	-41.52%	-60.09%	-133.95%	-276.39%	-713.49%	-3,622.65%	-	-	-
Net Profit Margin TTM	-25.32%	-27.32%	-30.08%	-39.04%	-54.68%	-123.38%	-258.64%	-675.24%	-3,487.13%	-	-	-
Growth Metrics
Net Revenue Growth (1Y)	149.04%	256.82%	432.05%	864.21%	3,421.98%	-	-	-	-	-	-	-
Net Income Growth (1Y)	15.32%	-20.98%	-38.12%	-44.26%	-44.77%	-11.86%	24.69%	49.33%	54.78%	41.16%	26.50%	26.77%
EPS Growth (1Y)	11.71%	-23.56%	-41.33%	-46.08%	-58.13%	-37.23%	9.54%	26.87%	32.42%	28.36%	16.01%	17.35%
Valuation Metrics
P/E TTM	-48.14	-49.11	-45.32	-35.67	-30.31	-23.76	-14.09	-8.90	-11.75	-12.02	-11.57	-7.77
P/B TTM	29.88	27.96	21.68	16.48	12.28	13.09	8.70	5.94	7.00	6.28	10.67	121.28
P/S TTM	12.19	13.42	13.63	13.92	16.57	29.31	36.44	60.08	409.63	-	-	-
Market Cap	15.65B	15.20B	13.06B	10.31B	8.54B	9.30B	6.56B	4.61B	6.00B	5.34B	4.32B	2.70B
Enterprise Value	15.70B	15.31B	13.20B	10.35B	8.47B	9.23B	6.58B	4.49B	5.61B	4.83B	4.34B	2.75B
Calculated Values
Free Cash Flow TTM	-207.07M	-273.19M	-190.80M	-161.63M	-308.39M	-396.41M	-457.03M	-433.32M	-450.82M	-391.12M	-325.71M	-303.28M
Net Debt	47.91M	108.14M	136.10M	39.06M	-72.82M	-70.64M	12.55M	-120.60M	-382.99M	-506.38M	15.57M	52.67M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
PEG Ratio
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
EV Revenue TTM
EV FCF TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-06-01Sale

Owner: Soergel, David

Title: Chief Medical Officer

Shares: 1,042

Price/Share: $495.74

Value: $516,561.08

Shares Owned: 10,033

Relationship: Officer

Ownership: Direct

2026-05-22Sale

Owner: Levy, Richard S

Title: -

Shares: 5,682

Price/Share: $513.83

Value: $2,919,582.06

Shares Owned: 22,015

Relationship: Director

Ownership: Direct

2026-05-18Sale

Owner: Soergel, David

Title: Chief Medical Officer

Shares: 844

Price/Share: $515.90

Value: $435,419.60

Shares Owned: 11,075

Relationship: Officer

Ownership: Direct

2026-03-06Sale

Owner: Dier, Mardi

Title: EVP and CFO

Shares: 1,982

Price/Share: $431.47

Value: $855,173.54

Shares Owned: 12,490

Relationship: Officer

Ownership: Direct

2026-03-06Sale

Owner: Sibold, William John

Title: President and CEO

Shares: 1,663

Price/Share: $431.94

Value: $718,316.22

Shares Owned: 161,829

Relationship: Director,Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-06-01	Soergel, David	Officer	Chief Medical Officer	Direct	Sale	1,042	495.74	$516,561.08	10,033	4
2026-05-22	Levy, Richard S	Director	-	Direct	Sale	5,682	513.83	$2,919,582.06	22,015	4
2026-05-18	Soergel, David	Officer	Chief Medical Officer	Direct	Sale	844	515.90	$435,419.60	11,075	4
2026-03-06	Dier, Mardi	Officer	EVP and CFO	Direct	Sale	1,982	431.47	$855,173.54	12,490	4
2026-03-06	Sibold, William John	Director,Officer	President and CEO	Direct	Sale	1,663	431.94	$718,316.22	161,829	4
2026-03-06	Kelley, Shannon T	Officer	General Counsel	Direct	Sale	360	431.94	$155,498.40	12,138	4
2026-03-06	Taub, Rebecca	Director	-	Direct	Sale	491	431.94	$212,082.54	452,213	4
2026-03-06	Huntsman, Carole	Officer	Chief Commercial Officer	Direct	Sale	419	431.94	$180,982.86	12,692	4
2026-03-02	Dier, Mardi	Officer	EVP and CFO	Direct	Sale	1,183	427.21	$505,389.43	9,257	4
2026-01-26	Taub, Rebecca	Director	-	Direct	Sale	647	492.42	$318,595.74	452,704	4
2026-01-26	Huntsman, Carole	Officer	Chief Commercial Officer	Direct	Sale	910	493.50	$449,085.00	9,122	4
2026-01-26	Sibold, William John	Director,Officer	President and CEO	Direct	Sale	1,577	492.42	$776,546.34	148,497	4
2026-01-20	Taub, Rebecca	Director	-	Direct	Sale	2,238	490.77	$1,098,343.26	453,351	4
2026-01-20	Kelley, Shannon T	Officer	General Counsel	Direct	Sale	692	496.08	$343,287.36	8,481	4
2026-01-09	Taub, Rebecca	Director	-	Direct	Sale	240	548.52	$131,644.80	455,589	4
2026-01-09	Friedman, Paul A	Director	-	Direct	Sale	280	551.24	$154,347.20	187,164	4
2025-12-10	Friedman, Paul A	Director	-	Direct	Sale	24,800	551.76	$13,683,648.00	187,164	4
2025-12-10	Taub, Rebecca	Director	-	Direct	Sale	18,650	551.79	$10,290,883.50	461,044	4
2025-12-04	Sibold, William John	Director,Officer	President and CEO	Direct	Sale	2,400	575.34	$1,380,816.00	150,074	4
2025-12-02	Dier, Mardi	Officer	EVP and CFO	Direct	Sale	4,173	581.45	$2,426,390.85	10,440	4
2025-11-21	Huntsman, Carole	Officer	Chief Commercial Officer	Direct	Sale	1,958	555.09	$1,086,866.22	10,032	4
2025-11-13	Levy, Richard S	Director	-	Direct	Sale	8,500	522.33	$4,439,805.00	21,197	4
2025-11-05	Bate, Kenneth	Director	-	Direct	Sale	16,575	485.61	$8,048,985.75	2,627	4
2025-09-09	Sibold, William John	Director,Officer	President and CEO	Direct	Sale	7,279	445.63	$3,243,740.77	102,474	4
2025-08-21	Sibold, William John	Director,Officer	President and CEO	Direct	Sale	7,616	400.52	$3,050,360.32	109,753	4
2025-08-20	Baker, Bros. Advisors (Gp…	Director	-	Indirect	Purchase	59,901	384.95	$23,058,889.95	1,947,968	4
2025-08-18	Baker, Felix, 667, L.P., …	Director	-	Indirect	Purchase	68,618	363.32	$24,930,291.76	1,859,091	4
2025-08-18	Kelley, Shannon T	Officer	General Counsel	Direct	Sale	1,304	371.08	$483,888.32	9,173	4
2025-08-15	Bate, Kenneth	Director	-	Direct	Sale	10,000	365.88	$3,658,800.00	2,627	4
2025-08-13	Friedman, Paul A	Director	-	Direct	Sale	129,172	366.29	$47,314,411.88	187,164	4
2025-08-12	Friedman, Paul A	Director	-	Direct	Sale	43,605	355.37	$15,495,908.85	187,164	4
2025-08-12	Taub, Rebecca	Director	-	Direct	Sale	43,263	355.31	$15,371,776.53	461,044	4
2025-07-18	Taub, Rebecca	Director	-	Direct	Sale	1,000	350.01	$350,010.00	461,044	4
2025-07-18	Friedman, Paul A	Director	-	Direct	Sale	1,400	350.03	$490,042.00	187,164	4
2025-07-17	Friedman, Paul A	Director	-	Direct	Sale	2,700	350.84	$947,268.00	187,164	4
2025-07-17	Taub, Rebecca	Director	-	Direct	Sale	2,657	350.79	$932,049.03	461,044	4
2025-03-13	Craves, Fred B	Director	-	Direct	Sale	7,742	326.58	$2,528,382.36	350,076	4
2025-03-10	Dier, Mardi	Officer	SVP and CFO	Direct	Sale	258	323.04	$83,344.32	10,440	4
2025-03-05	Waltermire, Robert E.	Officer	Senior VP, Chief Pharma Dev.	Direct	Sale	14,113	340.42	$4,804,347.46	3,728	4
2025-03-03	Dier, Mardi	Officer	SVP and CFO	Direct	Sale	1,961	324.72	$636,775.92	6,914	4
2025-03-03	Kelley, Shannon T	Officer	General Counsel	Direct	Sale	415	335.00	$139,025.00	7,290	4
2025-03-03	Huntsman, Carole	Officer	Chief Commercial Officer	Direct	Sale	1,834	323.86	$593,959.24	8,604	4
2025-02-28	Waltermire, Robert E.	Officer	Senior VP, Chief Pharma Dev.	Direct	Sale	1,227	341.27	$418,738.29	3,728	4
2025-02-27	Bate, Kenneth	Director	-	Direct	Sale	20,000	355.92	$7,118,400.00	1,912	4
2025-02-27	Daly, James M	Director	-	Direct	Sale	15,470	347.74	$5,379,537.80	1,912	4
2025-01-24	Waltermire, Robert E.	Officer	Senior VP, Chief Pharma Dev.	Direct	Sale	103	335.24	$34,529.72	4,955	4
2025-01-24	Taub, Rebecca	Director,Officer	Pres., R&D, and CMO	Direct	Sale	648	335.24	$217,235.52	456,662	4
2025-01-24	Huntsman, Carole	Officer	Chief Commercial Officer	Direct	Sale	347	335.24	$116,328.28	10,438	4
2025-01-24	Sibold, William John	Director,Officer	President and CEO	Direct	Sale	1,584	335.24	$531,020.16	54,303	4
2025-01-17	Taub, Rebecca	Director,Officer	Pres., R&D, and CMO	Direct	Sale	1,689	273.41	$461,789.49	457,310	4
2025-01-17	Kelley, Shannon T	Officer	General Counsel	Direct	Sale	277	273.41	$75,734.57	7,705	4
2025-01-17	Waltermire, Robert E.	Officer	Senior VP, Chief Pharma Dev.	Direct	Sale	442	273.41	$120,847.22	5,058	4
2024-12-03	Craves, Fred B	Director	-	Indirect	Sale	3,600	315.55	$1,135,980.00	11,000	4
2024-11-25	Craves, Fred B	Director	-	Indirect	Sale	3,400	350.40	$1,191,360.00	14,600	4
2024-11-21	Huntsman, Carole	Officer	Chief Commercial Officer	Direct	Sale	688	316.92	$218,040.96	10,785	4
2024-11-07	Levy, Richard S	Director	-	Direct	Sale	5,000	350.00	$1,750,000.00	11,012	4
2024-11-01	Levy, Richard S	Director	-	Direct	Sale	5,000	301.97	$1,509,850.00	11,012	4
2024-09-09	Sibold, William John	Director,Officer	President and CEO	Direct	Sale	6,363	243.83	$1,551,490.29	55,887	4
2024-06-14	Waltermire, Robert E.	Officer	Senior VP, Chief Pharma Dev.	Direct	Sale	1,900	280.00	$532,000.00	5,500	4
2024-06-12	Waltermire, Robert E.	Officer	Senior VP, Chief Pharma Dev.	Direct	Sale	2,000	285.00	$570,000.00	5,500	4
2024-05-21	Waltermire, Robert E.	Officer	Senior VP, Chief Pharma Dev.	Direct	Sale	1,036	231.34	$239,668.24	5,500	4
2024-05-14	Craves, Fred B	Director	-	Direct	Sale	22,489	215.40	$4,844,130.60	413,362	4
2024-04-08	Friedman, Paul A	Director	-	Direct	Sale	26,270	245.85	$6,458,479.50	185,735	4
2024-04-08	Taub, Rebecca	Director,Officer	Pres., R&D, and CMO	Direct	Sale	2,676	246.18	$658,777.68	458,999	4
2024-04-05	Taub, Rebecca	Director,Officer	Pres., R&D, and CMO	Direct	Sale	27,506	242.86	$6,680,107.16	458,999	4
2024-04-05	Friedman, Paul A	Director	-	Direct	Sale	27,613	243.19	$6,715,205.47	185,735	4
2024-04-02	Bate, Kenneth	Director	-	Direct	Sale	11,212	246.16	$2,759,945.92	1,198	4
2024-04-02	Daly, James M	Director	-	Direct	Sale	10,912	245.69	$2,680,969.28	1,198	4
2024-04-01	Levy, Richard S	Director	-	Direct	Sale	11,000	260.35	$2,863,850.00	10,298	4
2023-12-15	Waltermire, Robert E.	Officer	Senior VP, Chief Pharma Dev.	Direct	Sale	2,000	238.50	$477,000.00	5,667	4
2023-12-14	Baker, Bros. Advisors Lp,…	Director	-	Indirect	Purchase	20,633	228.37	$4,711,958.21	1,793,403	4
2023-12-13	Waltermire, Robert E.	Officer	Senior VP, Chief Pharma Dev.	Direct	Sale	2,500	225.50	$563,750.00	5,667	4
2023-12-12	667,, L.P., Baker Bros. A…	Director	-	Indirect	Purchase	34,578	213.61	$7,386,206.58	1,699,129	4
2023-12-05	Lynch, Brian Joseph	Officer	SVP and General Counsel	Direct	Sale	1,000	227.33	$227,330.00	15,001	4
2023-11-30	Lynch, Brian Joseph	Officer	SVP and General Counsel	Direct	Sale	3,000	204.58	$613,740.00	15,001	4
2023-11-21	Baker, Julian, Baker Bros…	Director	-	Indirect	Purchase	64,350	187.21	$12,046,963.50	1,667,104	4
2023-11-20	Baker, Brothers Life Scie…	Director	-	Indirect	Purchase	20,709	186.18	$3,855,601.62	1,607,668	4
2023-11-15	Baker, Julian, Baker Feli…	Director	-	Indirect	Purchase	15,199	161.97	$2,461,782.03	1,545,775	4
2023-11-14	Baker, Felix, Baker Bros.…	Director	-	Indirect	Purchase	37,660	153.55	$5,782,693.00	1,500,227	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

79.38%

Inst. Shares: 23,046,789

Shares Outstanding: 29,032,422

2025-12-31

102.13%

Inst. Shares: 22,912,760

Shares Outstanding: 22,434,310

2025-09-30

101.57%

Inst. Shares: 22,836,155

Shares Outstanding: 22,482,502

2025-06-30

80.64%

Inst. Shares: 22,766,497

Shares Outstanding: 28,232,604

2025-03-31

81.06%

Inst. Shares: 22,765,549

Shares Outstanding: 28,085,234

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	23,046,789	29,032,422	79.38%
2025-12-31	22,912,760	22,434,310	102.13%
2025-09-30	22,836,155	22,482,502	101.57%
2025-06-30	22,766,497	28,232,604	80.64%
2025-03-31	22,765,549	28,085,234	81.06%
2024-12-31	22,064,184	21,272,962	103.72%
2024-09-30	21,603,683	21,745,929	99.35%
2024-06-30	21,467,956	21,402,646	100.31%
2024-03-31	19,566,619	20,001,569	97.83%
2023-12-31	18,756,345	18,687,774	100.37%
2023-09-30	16,491,716	18,476,414	89.26%
2023-06-30	14,164,637	18,310,952	77.36%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

MADRIGAL PHARMACEUTICALS, INC. (MDGL) — SEC Financial Statements & Analysis

MADRIGAL PHARMACEUTICALS, INC. (MDGL) is a pharmaceutical preparations company, incorporated in DE. MADRIGAL PHARMACEUTICALS, INC. trades on Nasdaq as: MDGL. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), MADRIGAL PHARMACEUTICALS, INC. reported a 149.04% year-over-year revenue growth, a Debt-to-Equity ratio of 1.38x, a Price-to-Sales (P/S) ratio of 12.19x (TTM), a Price-to-Book (P/B) ratio of 29.88x (TTM), at a market cap of $15.65B. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: 149.04%
Debt To Equity: 1.38x
P/S TTM: 12.19x
P/B TTM: 29.88x
Market Cap: $15.65B

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is MADRIGAL PHARMACEUTICALS, INC. in?

MADRIGAL PHARMACEUTICALS, INC. (MDGL) operates in the Pharmaceutical Preparations industry.

What is MDGL's market cap?

MADRIGAL PHARMACEUTICALS, INC. (MDGL) has a market capitalization of $15.65B as of 2026-06-30.

What exchange does MDGL trade on?

MADRIGAL PHARMACEUTICALS, INC. (MDGL) trades on the Nasdaq.

Where is MADRIGAL PHARMACEUTICALS, INC. incorporated?

MADRIGAL PHARMACEUTICALS, INC. is incorporated in DE.